Shares Magazine
234.00p+7.50 (+3.31%)02 May 2025, 14:50
Jump to:
Hutchmed (China) Limited Fundamentals
| Company Name | Hutchmed (China) Limited | Last Updated | 2025-05-02 |
|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Sector | Healthcare |
| Shares in Issue | 854.884 m | Market Cap | £2.00 bn |
| PE Ratio | 77.11 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | $0.04 | EPS Growth (%) | -0.65 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.0705 | Debt Equity Ratio | 0.0836 |
| Asset Equity Ratio | 1.6508 | Cash Equity Ratio | 1.0833 |
| Quick Ratio | 2.6658 | Current Ratio | 2.83 |
| Price To Book Value | 3.3944 | ROCE | 0 |
Hutchmed (China) Limited Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Hutchmed (China) Limited Company Financials
| Assets | 2024 | 2023 | 2022 |
|---|---|---|---|
| Tangible Assets | $97.00 m | $104.39 m | $84.67 m |
| Intangible Assets | 0 | 0 | 0 |
| Investments | $82.77 m | $48.41 m | $73.78 m |
| Total Fixed Assets | $207.64 m | $182.93 m | $189.56 m |
| Stocks | $50.40 m | $50.26 m | $56.69 m |
| Debtors | $167.74 m | $149.91 m | $127.17 m |
| Cash & Equivalents | $836.11 m | $886.34 m | $631.00 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | $1.27 bn | $1.28 bn | $1.03 bn |
| Liabilities | 2024 | 2023 | 2022 |
|---|---|---|---|
| Creditors within 1 year | $376.56 m | $403.03 m | $353.90 m |
| Creditors after 1 year | $125.78 m | $133.36 m | $38.67 m |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | $502.34 m | $536.39 m | $392.57 m |
| Net assets | $771.85 m | $743.39 m | $636.87 m |
| Equity | 2024 | 2023 | 2022 |
|---|---|---|---|
| Called up share capital | $87.16 m | $87.13 m | $86.48 m |
| Share Premium | $1.52 bn | $1.52 bn | $1.50 bn |
| Profit / Loss | -$1.11 m | $58.31 m | -$410.42 m |
| Other Equity | $759.93 m | $730.54 m | $610.37 m |
| Preference & Minorities | $11.92 m | $12.85 m | $26.50 m |
| Total Capital Employed | $771.85 m | $743.39 m | $636.87 m |
| Ratios | 2024 | 2023 | 2022 |
|---|---|---|---|
| Debt Ratio | $0.08 | $0.07 | $0.04 |
| Debt-to-Equity | $0.08 | $0.07 | $0.04 |
| Assets / Equity | 1.6508 | 1.6508 | 1.6508 |
| Cash / Equity | 1.0833 | 1.0833 | 1.0833 |
| EPS | $0.04 | $0.13 | -$0.43 |
| Cash Flow | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash from operating activities | $497,000.00 | $219.26 m | -$268.60 m |
| Cashflow before financing | -$30.17 m | $267.92 m | -$351.36 m |
| Increase in Cash | -$126.23 m | -$23.22 m | -$54.77 m |
| Income | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | $630.20 m | $838.00 m | $426.41 m |
| Cost of sales | $348.88 m | $384.45 m | $311.10 m |
| Gross Profit | $281.32 m | $453.55 m | $115.31 m |
| Operating Profit | 0 | 0 | 0 |
| Pre-Tax profit | -$1.11 m | $58.31 m | -$410.42 m |
Hutchmed (China) Limited Company Background
| Sector | Healthcare |
|---|---|
| Activities | HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolioof several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures. |
| Latest Interim Date | 31 Jul 2024 |
| Latest Fiscal Year End Date | 19 Mar 2025 |
Hutchmed (China) Limited Directors
| Appointed | Name | Position |
|---|---|---|
| 2024-10-21 | Mr. Graeme Allan Jack | Non-Executive Director |
| 2024-10-21 | Mr. Dan Eldar | Non-Executive Director,Chairman |
| 2024-04-08 | Ms. Edith Shih | Non-Executive Director,Company Secretary |
| 2024-10-21 | Mr. Paul Rutherford Carter | Non-Executive Director,Senior Independent Director |
| 2017-02-01 | Mr. Christopher John Nash | Director |
| 2024-05-17 | Mr. Chi Keung Simon To | Executive Director,Chairman |
| 2022-03-03 | Mr. Christian Hogg | Executive Director,Chief Executive Officer |
| 2017-03-01 | Mr. Michael William Davis Howell | Director |
| 2017-02-01 | Professor Christopher Huang | Non-Executive Director |
| 2024-03-05 | Mr. Johnny Cheng Chig FUNG | Executive Director,Chief Financial Officer |
| 2023-05-12 | Dr. Karen Jean Ferrante, M.D. | Non-Executive Director |
| 2025-03-14 | Dr. Weiguo Su | Executive Director,Chief Executive Officer and Chief Scientific Officer |
| 2024-10-21 | Professor Shu Kam Tony Mok | Non-Executive Director |
| 2024-05-08 | Dr. Renu Bhatia | Non-Executive Director |
Hutchmed (China) Limited Contact Details
| Company Name | HUTCHMED (China) Ltd |
|---|---|
| Address | Ugland House, P.O. Box 309, Grand Cayman, KY1-1104 |
| Telephone | +852 21281188 |
| Website | https://www.hutch-med.com |
Hutchmed (China) Limited Advisors
| Financial PR Adviser | BMC Communications |
|---|---|
| Phone | +1 646 513-3125 |
| Financial PR Adviser | The Trout Group |
|---|---|
| Phone | +86 15821996861 |
| Fax | +86 16463782901 |
| Registrar | Computershare Investor Services Ltd |
|---|---|
| Phone | +44 8707074040 |
| Fax | +44 3708735851 |
| Auditor | PricewaterhouseCoopers |
|---|---|
| Phone | +852 22898888 |
| Fax | +852 28109888 |
| Stockbroker | Panmure Gordon (UK) Ltd |
|---|---|
| Phone | +44 2078862500 |
| Stockbroker | UBS Limited |
|---|---|
| Phone | +44 2075678000 |
| Solicitor | DLA Piper LLP |
|---|---|
| Phone | +44 8700111111 |
| Fax | +44 2077966666 |
| Financial PR Adviser | Citigate Dewe Rogerson |
|---|---|
| Phone | +44 2076389571 |
| Nominated Adviser | Panmure Gordon (UK) Ltd |
|---|---|
| Phone | +44 2078862500 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Ferrexpo PLC | 79.70 | 10.70 |
| Senior PLC | 146.09 | 6.17 |
| Clarkson PLC | 3,155.00 | 5.34 |
| Harbour Energy PLC | 160.90 | 5.23 |
| Alfa Financial Software Holdings PLC | 230.50 | 4.77 |
| Ssp Group PLC | 156.60 | 3.92 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Mobico Group PLC | 30.82 | -2.96 |
| Spectris PLC | 2,020.66 | -2.95 |
| Watches Of Switzerland Group PLC | 346.20 | -3.51 |
| Sirius Real Estate LD | 93.25 | -2.66 |
| Just Group PLC | 138.40 | -2.67 |
| Lion Finance Group PLC | 6,065.00 | -2.26 |